Growth Metrics

Biogen (BIIB) Change in Receivables (2016 - 2026)

Biogen has reported Change in Receivables over the past 18 years, most recently at -$103.4 million for Q1 2026.

  • For Q1 2026, Change in Receivables fell 46.88% year-over-year to -$103.4 million; the TTM value through Mar 2026 reached -$135.7 million, up 46.15%, while the annual FY2025 figure was -$102.7 million, 53.8% up from the prior year.
  • Change in Receivables for Q1 2026 was -$103.4 million at Biogen, up from -$114.5 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $240.9 million in Q2 2025 and troughed at -$238.2 million in Q4 2024.
  • A 5-year average of -$16.8 million and a median of -$40.7 million in 2024 define the central range for Change in Receivables.
  • On a YoY basis, Change in Receivables climbed as much as 748.24% in 2025 and fell as far as 662.77% in 2025.
  • Year by year, Change in Receivables stood at $200.4 million in 2022, then plummeted by 168.76% to -$137.8 million in 2023, then crashed by 72.86% to -$238.2 million in 2024, then skyrocketed by 51.93% to -$114.5 million in 2025, then grew by 9.69% to -$103.4 million in 2026.
  • Business Quant data shows Change in Receivables for BIIB at -$103.4 million in Q1 2026, -$114.5 million in Q4 2025, and -$158.7 million in Q3 2025.